The Traverse trial found that testosterone supplementation to a eugonadal level did not lead to a higher incidence of prostate cancer diagnosis compared to placebo in hypogonadal men with symptoms.

“so what what the study tells us is is it's reassuring in many many ways number one men with low PSAs have a low risk of being diagnosed with prostate cancer number two you can use PSA in generally similar Fashions when you're supplementing a man uh on um supplement on exogenous testosterone that is you can look at changes in the PSA”